History 11 items

Trials, agents, guidance

• Guideline Where the HDL hypothesis stands after the CETP trialsEditorial position of this site, not a society document

Studies

• Landmark Nature paper shows CETP-expressing transgenic mice develop far worse atherosclerosis than non-expressing controls (Nature 1993)Nature · July 1993 9
• Landmark purification establishes human CETP as a unique 74-kDa hydrophobic plasma apolipoprotein (J Biol Chem 1987)J Biol Chem · February 1987 9
• Landmark 1978 paper reports the original isolation of the human cholesteryl ester transfer protein itself (Proc Natl Acad Sci USA 1978)Proc Natl Acad Sci U S A · July 1978 9
• Medicinal chemistry paper describes the structure-activity work that led to the discovery of anacetrapib (J Med Chem 2011)J Med Chem · June 2011 7
• The human CETP gene spans 25 kb with 16 exons and shares a signal-sequence motif with lipoprotein lipase and apoA-I/A-IV (Biochemistry 1990)Biochemistry · February 1990 7
• CETP inhibitors, state of the science: why torcetrapib, dalcetrapib, anacetrapib and evacetrapib failed and why obicetrapib is different (Curr Cardiol Rep 2026)Curr Cardiol Rep · January 2026 6
• Only 42% of 96,944 CETP-inhibitor trial subjects ever appeared in a published report, a case study in biomarker-driven drug development finds (Circ Cardiovasc Qual Outcomes 2017)Circ Cardiovasc Qual Outcomes · June 2017 6
• CETP inhibitors, challenges and perspectives: off-target failure for torcetrapib, futility for dalcetrapib and evacetrapib, early promise for anacetrapib and TA-8995 (Expert Rev Cardiovasc Ther 2016)Expert Rev Cardiovasc Ther · May 2016 5
• Early review surveys progress toward antisense and small-molecule CETP inhibitors as HDL-raising therapies (Curr Opin Drug Discov Devel 2001)Curr Opin Drug Discov Devel · September 2001 5

Timeline

• CETP deficiency described in Japan1 November 1989